Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity

Rheumatology International

Volumn 35, Issue 8, 2015, Pages 1385-1392

  Yilmazer, Baris ^a   Sahin, Tayfun ^b   Unlu, Berrin Öztaş ^c   Kir, Hale Maral ^b   Cefle, Ayse ^b  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Asymmetric dimethylarginine; Endothelial dysfunction; Psoriatic arthritis; Subclinical atherosclerosis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; N(G),N(G) DIMETHYLARGININE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ARGININE; N,N-DIMETHYLARGININE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAS28; DISEASE ACTIVITY; ECHOGRAPHY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; MINIMAL DISEASE ACTIVITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RISK ASSESSMENT; SUBCLINICAL ATHEROSCLEROSIS; VASODILATATION; ANALOGS AND DERIVATIVES; ASYMPTOMATIC DISEASE; ATHEROSCLEROTIC PLAQUE; BLOOD; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CAROTID ARTERY; COMPLICATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIUM;

ADULT; ARGININE; ARTHRITIS, PSORIATIC; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; SEVERITY OF ILLNESS INDEX; VASODILATION;

EID: 84931566812     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3228-y     Document Type: Article

References (45)

1. Gladman DD (2004) Psoriatic arthritis. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, Breedveld F (eds) Oxford textbook of rheumatology, 3rd edn. Oxford University Press, Oxford, pp 766–778
2. Wong D, Gladman DD, Husted J, Long JA, Farewell VT (1997) Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40:1868–1872
3. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G (2011) Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 31(3):705–712 CaRRDs study group
4. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(24):2957–2963
5. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Wong KC, Li TK, Yu T, Zhu TY, Kun EW, Yip GW, Yu CM (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59(9):1322–1331
6. Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, Rosen CF, Gladman DD (2013) The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis 72(5):715–720
7. Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD, Longhi M, Sitia S, Bianchi M, Ferrario P, Doria A, De Gennaro CV, Sarzi-Puttini P (2009) Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 48(7):834–839
8. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99(9):1141–1146
9. Vallance P (2001) Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358(9299):2096–2097
10. Atzeni F, Sarzi-Puttini P, Sitia S, Tomasoni L, Gianturco L, Battellino M, Boccassini L, De Gennaro CV, Marchesoni A, Turiel M (2011) Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 38(8):1661–1664
11. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J et al (2005) Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23(2):233–246
12. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S et al (2005) Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23(1):7–17
13. Nadar S, Blann AD, Lip GY (2004) Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 10(29):3591–3605
14. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4):459–467
15. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57(2):287–293
16. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:1074–1080
17. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53
18. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673 CASPAR study group
19. van der Heijde DM, van’t Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51(2):177–181
20. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, Herdman M, Firth P, Hotchkiss K (2006) A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis area and severity index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol 155:707–713
21. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2):137–145
22. Committee Guidelines (2003) European society of Hypertension-European society of cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011–1013
23. Persson J, Stavenow L, Wikstrand J, Israelsson B, Formgren J, Berglund G (1992) Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 12(2):261–266
24. Roman MJ, Saba PS, Pini R, Spitzer M, Pickering TG, Rosen S, Alderman MH, Devereux RB (1992) Parallel cardiac and vascular adaptation in hypertension. Circulation 86(6):1909–1918
25. Joakimsen O, Bønaa KH, Stensland-Bugge E (1997) Reproducibility of ultrasound assessment of carotid plaque occurrence, thickness, and morphology the Tromsø study. Stroke 28(11):2201–2207
26. Celermajer DS, Sorensen KE, Gooch VM et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115
27. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371–1375
28. Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41(6):1103–1110
29. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19(3):225–230
30. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls–the role of inflammation. Rheumatology (Oxford) 47(5):718–723
31. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, Comaneshter D, Paran D, Wigler I, Levartovsky D, Berliner S, Elkayam O (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36(4):203–209
32. Syngle A, Vohra K, Sharma A, Kaur L (2010) Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 29(7):763–770
33. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA (2004) Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 51(3):447–450
34. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, Ferraccioli G (2007) TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 27(7):833–839
35. Spinelli FR, Metere A, Barbati C, Pierdominici M, Iannuccelli C et al (2013) Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators Inflamm. doi:10.1155/2013/537539
36. Vallance P, Leone A, Calver A, Collier J (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339(8793):572–575
37. Surdacki A, Martens-Lobenhoffer J, Wloch A et al (2007) Elevated plasma asymmetric dimethyl-l-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arth Rheum 56(3):809–819
38. Di Franco M, Spinelli FR, Metere A et al (2012) Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm. doi:10.1155/2012/347268
39. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, Bitterman H, Feld J, Rimar D, Rosner I (2008) Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 35(5):877–882
40. Tam LS, Li EK, Shang Q, Tomlinson B, Li M, Leung YY, Kuan WP, Kwok LW, Li TK, Zhu Y, Kun EW, Yip G, Yu CM (2011) Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 70(4):705–706
41. Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46(4):862–873
42. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35(1):8–17
43. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C et al (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57(1):125–132
44. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63(1):31–35
45. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J et al (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 114(8):647–652